In macaques, the route of immunization has a profound effect on the immune response. Augmenting rectal or vaginal immunization with oral or nasal immunization enhanced the secretory IgA, serum IgG, and T cell responses. However, targeted iliac lymph node (TILN) immunization with recombinant simian immunodeficiency virus (SIV) gp120 and p27 elicited the most consistent mucosal antibody responses in the rectum, vagina, urine, seminal fluid, and blood. Both mucosal and TILN immunization induced specific CD4 + T cell proliferative responses in the iliac lymph nodes, which drain these mucosal surfaces, and in the splenic and circulating T cells. Rectal mucosal challenge with cell-free SIV induced total protection in 4 of 7 macaques that were immunized by the TILN route, and, compared with unimmunized macaques or those immunized by the mucosal route ( ), it induced a 190% decrease P ! .001 in virus load in 3 of them. Protection from mucosal rectal infection with SIV was significantly associated with an increase in the CD8 suppressor factor (which was generated by the iliac lymph node), RANTES, and MIP-1b ( ) . P!.01
augmented by oral and then intramuscular (IM) immunization. Indeed, augmenting genital immunization by oral immunization in female [5] or male macaques [6] or augmenting rectal immunization by oral immunization [7] induced s-IgA and IgG antibodies to p27 at the corresponding mucosal surface. Serum antibodies and CD4 ϩ T cell proliferative responses to p27 were also elicited by the 3 routes of immunization. Autopsy examination of these macaques showed T and B cell responses in the internal iliac lymph node cells, in contrast to the responses after systemic immunization [8] . Furthermore, augmenting oral (or intratracheal) immunization by prior IM immunization with SIV induced vaginal IgG and IgA antibodies to SIV, and 5 of 6 macaques were protected when challenged by the vaginal route [4] .
Targeted Lymph Node Immunization
As an alternative strategy, a subcutaneous immunization technique, which aims to administer the vaccine in the proximity of the internal and external iliac lymph nodes, was developed [8] . The same antigen as that administered in the augmented mucosal immunization (p27:Ty-VLP) was used, except aluminium hydroxide was used as an adjuvant. Significant concentrations of s-IgA (and IgG) antibodies to p27 were found after the second immunization, in the rectal washings and urine of male and female macaques, in vaginal washings of female macaques, and in urethral washings and ejaculates of male macaques. Serum IgA antibody titers to p27 were higher than the corresponding IgG titers. Targeted lymph node immunization elicited a pattern of responses to p27 in the lymph nodes similar to that elicited by the three mucosal routes (internal and external iliac, inferior mesenteric, and iliac-paraortic) and JID 1999;179 (Suppl 3) by the splenic and circulating T lymphocytes. The proliferative T cells belonged to the CD4 ϩ subset, irrespective of the route of immunization.
Localization of specific T and B cells to the draining lymph nodes of the genitourinary and rectal tracts might be essential in preventing transmission of human immunodeficiency virus (HIV) or SIV by infected Langerhans' cells, dendritic cells, or macrophages from the mucosal tissues to the lymph nodes. These T and B cell functions might prevent formation of a viral reservoir in the draining lymph nodes if the mucosal immune barrier were breached. The significance of this observation has been strengthened by reports that HIV is found in the lymph nodes early in infection [9] and that the virus particles are bound to follicular dendritic cells as immune complexes [10, 11] . A central immune barrier is comparable to that found after IM immunization (in that splenic and circulating proliferative and helper T cells are found), and sensitized B cells and IgG and IgA antibodies are also induced.
Mucosal Immunity in Protection against Rectal Mucosal Challenge by Live SIV
In the next series of experiments, prevention of rectal SIV infection by immunization with SIV gp120 and core p27 antigens in alum by the targeted iliac lymph node (TILN) route was compared with the combined naso-rectal-IM route of immunization.
In series 1, a group of 4 male rhesus monkeys (Macaca mulatta) were immunized three times at about monthly intervals, by the subcutaneous TILN route [12] , with gp120 and p27 (200 mg each) in alum (AluGel; Uniscience, London). Another group of 4 control macaques were not immunized. Recombinant SIV mac251 gp120 was expressed in recombinant baculovirus-infected cells [13] , and recombinant SIV p27 was expressed in pGEX-3X as a glutathione S-transferase fusion protein.
In the second series of experiments, ∼14 weeks later, 10 male rhesus monkeys were used, of which 6 were immunized and 4 were unimmunized. Three macaques were immunized three times by the TILN route, as in series 1, but a fourth 100-mg dose of the vaccine was also injected IM into each buttock. Three macaques were given the same vaccine, except that for the vaccines administered by the mucosal routes, SIV gp120 and p27 were covalently linked to the mucosal adjuvant cholera toxin B subunit (Sigma, Poole, United Kingdom). The vaccine was administered monthly by means of lubricated pediatric nasogastric tubes via the nasal route (2 times), the rectal route (3 times), and then IM into the buttock (1 time). The control group consisted of 4 unimmunized macaques.
Isolation of Virus after Rectal Mucosal Challenge
In the first series, 8 macaques were challenged ∼2 weeks after the last immunization with 9500 TCID 50 , which was equivalent to at least 34 median monkey infectious doses of the SIV mac 32H J5 molecular clone [14] . Total protection was found by coculture and nested polymerase chain reaction in 2 of the 4 immunized macaques and by a decrease of 94% and 97.4% in virus load in the 2 other immunized macaques (table 1) . In contrast, all 4 unimmunized control macaques were infected. Analysis of variance of virus load between the 4 immunized and 4 control macaques over the experimental period was very significant ( , ). F ϭ 5.86 P ! .001 In the second series, 2 macaques remained free of any detectable virus in peripheral blood mononuclear cells (PBMC), as determined by coculture and nested polymerase chain reaction. The third macaque showed a transient infection, with virus being isolated only at weeks 2 and 6 (3509 and 5.5 cells/ 10 6 PBMC, respectively) (table 1). In contrast, 3 of the 4 unimmunized controls became infected after rectal challenges with SIV. Surprisingly, all 3 macaques that were immunized 2 times via the nasal route followed by 3 times via the rectal route and 1 time IM (gluteal) became infected (table 1).
Antibody Responses
All immunized macaques, irrespective of the route of immunization, developed s-IgA and IgG antibodies to gp120 and p27 in rectal washings after their last immunization; antibodies were not detected in preimmunized and unimmunized macaques (data not presented). In contrast, urinary s-IgA and IgG antibodies were detected only in TILN-immunized macaques, suggesting a regional immune response. TILN immunization, especially with an IM boost, elicited the highest serum IgA and IgG antibody titers (up to 1:6400, with one at 1:25,600) to both gp120 and p27. However, the antibody levels failed to differentiate between total, partial, or no protection in the immunized macaques. Serum neutralizing antibodies, which were determined by T. Corcoran (National Institute of Biological Standards and Control, Potters Bar, United Kingdom), had low titers and were not correlated with protection (results not presented).
T Cell Proliferative Responses
T cell stimulation with gp120 and p27 significantly increased proliferation (stimulation index ) in all immunized ma-1 3 caques. The lack of protection in the naso-rectal-IM immunized macaques, despite significant T cell responses to gp120 and p27 in all 3 macaques, suggests that the T cell responses were not protective.
CD8 Suppressor Factor (CD8-SF)
CD8-SF was assayed [15] from PBMC and iliac and axillary lymph nodes in 10 macaques as described elsewhere [12] . On day 9, SIV replication was assayed by determining reverse transcriptase (RT) activity by use of the RT detection and quantification method (Quan-T-RT assay kit; Amersham Life Sciences, Amersham, United Kingdom). Significant variation in inhibition of replication of SIV in CD4 ϩ T cells was found within iliac lymph node CD8-SF and PBMC (table 2; analysis  of variance,  ,  ) . CD8-SF generated from the F ϭ 4.437 P ! .05 unrelated axillary lymph nodes as well as PBMC failed to show a significant variation in SIV inhibition (table 2) . Furthermore, the TILN-immunized macaques showed a significant increase in CD8-SF activity when compared with the immunized control or unprotected macaques (unpaired , ). t test ϭ 4.286 P ! .01 Comparison of CD8 suppression between the iliac and axillary lymph nodes of the TILN-immunized macaques also showed significantly higher suppression of SIV replication in the iliac lymph node cells (paired , ). It is notet test ϭ 6.318 P ! .05 worthy that the only unimmunized macaque that was not infected after rectal challenge yielded the highest CD8-SF (198%) not only in the iliac but also in the axillary lymph nodes.
The Chemokines, RANTES, MIP-1a, and MIP-1b RANTES, MIP-1a, MIP-1b, and interleukin (IL)-8 chemokines were assayed in the culture supernatants generated for the CD8-SF from PBMC and iliac and axillary lymph nodes [12] . Specific EIAs were used (R&D Systems Europe, Abingdon, United Kingdom). Levels of the b chemokines varied significantly from the group means in the iliac lymph nodes of infected macaques ( ) were significantly increased in TILN-P ! .01 immunized macaques compared with concentrations of the other b chemokines. Although levels of MIP-1a and the unrelated chemokine IL-8 also varied significantly from the group means ( ), levels for the TILN-immunized macaques did P ! .025 not vary significantly from those for the infected macaques in the other groups. Similar analysis of the levels in axillary lymph node cells failed to show a significant increase (except for MIP1b) in the TILN-immunized macaques compared with levels in the infected macaques from other groups. Furthermore, compared with the axillary lymph nodes of the TILN-immunized macaques, the iliac lymph nodes had significantly increased concentrations of RANTES ( ), MIP-1a ( ), and P ! .01 P ! .025 MIP-1b ( ) but not IL-8 (table 2) . P ! .05 The results of these experiments suggest that in addition to B and T cell immunity, TILN immunization elicits effective CD8-SF, RANTES, MIP-1a, and MIP-1b, which are associated with protection from rectal mucosal infection with live SIV. There is growing evidence that CD8-SF and the three bchemokines can block or inhibit SIV or HIV infection when an inhibitory concentration is reached. RANTES has been shown in vitro to bind to CCR5, thereby preventing binding of SIV or HIV [16] . In addition, the CCR5 is internalized and therefore may not be available for SIV or HIV to bind, although in vitro the CCR5 is rapidly recycled to the surface. The most convincing evidence of the requirement for CCR5 in HIV infection is in subjects with the homozygous 32-bp deletion: Such persons are protected from HIV infection [17] [18] [19] .
